PIONEER: This trial is trying to determine the best way of delivering radiation therapy to the breast tissue of people diagnosed with invasive, Grade 1, 2 or 3 breast cancer, before surgeryA Pilot Study of Prone Position Neoadjuvant Breast Radiotherapy to Reduce Skin Toxicity

Inclusion

Patient has provided written informed consent for the trial
Female patients greater than or equal 18 years of age on day of signing informed consent
Patient has histologically confirmed invasive, Grade 1, 2 or 3 breast carcinoma
Primary tumour is T2, T3 or T4 and N1+
Patient is a candidate for radiotherapy in the prone position and mastectomy with immediate autologous reconstruction as assessed by the breast surgeon, the plastic surgeon and the radiation oncologist
Patient has received neoadjuvant systemic therapy, including chemotherapy and/or targeted therapies
Patient ECOG Performance status of 0 or 1
Patient is willing and able to comply with the protocol requirements for the duration of the study including undergoing radiotherapy, surgery, scheduled visits and follow up